Maze Therapeutics, Inc. (MAZE:NASDAQ) closed at $31.01 on October 23, 2026, down 2.94% on the day. The stock trades 42.2% below its 52-week high of $53.65 and 41.3% above its 52-week low of $21.95. Over the past year, it gained 2.0%. Maze Therapeutics, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, MAZE closed higher on 126 days (50%). Its best day was September 22, 2026 (+26.75%) and its worst was March 25, 2026 (-35.24%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 1 time.
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease. We initiated a Phase 2 trial of our lead drug candidate, MZE829, in November 2024.
Find more stocks like MAZE with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.